Addition of Everolimus and Trastuzumab to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer

Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2018.12.017
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Trastuzumab in the Treatment of Metastatic Breast Cancer : Anticancer Therapy Versus Cardiotoxicity

Circulation
Cardiovascular MedicinePhysiologyCardiology
2000English

Phase II Study of Pembrolizumab and Capecitabine for Triple Negative and Hormone Receptor-Positive, HER2−negative Endocrine-Refractory Metastatic Breast Cancer

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

Trastuzumab-Containing Regimens for Metastatic Breast Cancer

Cochrane Database of Systematic Reviews
2014English

How to Overcome Endocrine Resistance in Early and Metastatic Breast Cancer

Chronicles of Oncology
2018English

Endocrine Therapy of Breast Cancer

2008English

HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2004English

How to Improve Endocrine Therapy of Breast Cancer

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
1990English

New Strategies in Metastatic Hormone Receptor–Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies

Clinical Cancer Research
Cancer ResearchOncology
2016English

Impact of Adding the Multikinase Inhibitor Sorafenib to Endocrine Therapy in Metastatic Estrogen Receptor-Positive Breast Cancer

Future Oncology
MedicineCancer ResearchOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy